SAVERONE 2014 LTD -ADR (SVRE)

US80516T1051 - ADR

1.1299  +0.06 (+5.6%)

After market: 1.13 +0 (+0.01%)

Fundamental Rating

2

Taking everything into account, SVRE scores 2 out of 10 in our fundamental rating. SVRE was compared to 124 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of SVRE have multiple concerns. SVRE is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

SVRE had negative earnings in the past year.
In the past year SVRE has reported a negative cash flow from operations.
In the past 5 years SVRE always reported negative net income.
SVRE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -146.86%, SVRE is doing worse than 95.93% of the companies in the same industry.
SVRE has a worse Return On Equity (-336.37%) than 95.12% of its industry peers.
Industry RankSector Rank
ROA -146.86%
ROE -336.37%
ROIC N/A
ROA(3y)-113.03%
ROA(5y)-427.84%
ROE(3y)-211.28%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 21.41%, SVRE is not doing good in the industry: 65.04% of the companies in the same industry are doing better.
SVRE's Gross Margin has improved in the last couple of years.
SVRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.63%
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

SVRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SVRE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SVRE has been increased compared to 5 years ago.
The debt/assets ratio for SVRE is higher compared to a year ago.

2.2 Solvency

SVRE has an Altman-Z score of -9.36. This is a bad value and indicates that SVRE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.36, SVRE is not doing good in the industry: 92.68% of the companies in the same industry are doing better.
SVRE has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.49, SVRE is doing worse than 75.61% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -9.36
ROIC/WACCN/A
WACC9.28%

2.3 Liquidity

SVRE has a Current Ratio of 1.81. This is a normal value and indicates that SVRE is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.81, SVRE is not doing good in the industry: 70.73% of the companies in the same industry are doing better.
SVRE has a Quick Ratio of 1.28. This is a normal value and indicates that SVRE is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SVRE (1.28) is worse than 69.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.28

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.35% over the past year.
Looking at the last year, SVRE shows a very negative growth in Revenue. The Revenue has decreased by -24.41% in the last year.
The Revenue has been growing by 104.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.75%
Revenue 1Y (TTM)-24.41%
Revenue growth 3Y104.94%
Revenue growth 5YN/A
Sales Q2Q%-67.25%

3.2 Future

SVRE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.89% yearly.
Based on estimates for the next years, SVRE will show a very strong growth in Revenue. The Revenue will grow by 88.54% on average per year.
EPS Next Y66.38%
EPS Next 2Y36.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-31.97%
Revenue Next 2Y88.54%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

1

4. Valuation

4.1 Price/Earnings Ratio

SVRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SVRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SVRE's earnings are expected to grow with 36.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.89%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

SVRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SAVERONE 2014 LTD -ADR

NASDAQ:SVRE (11/22/2024, 8:00:00 PM)

After market: 1.13 +0 (+0.01%)

1.1299

+0.06 (+5.6%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap22.54M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -146.86%
ROE -336.37%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 21.41%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.81
Quick Ratio 1.28
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)43.35%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y66.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-24.41%
Revenue growth 3Y104.94%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y